Pharma’s pipeline continues to provide drama as investors look beyond COVID in Q4While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning Share XPharma’s pipeline continues to provide drama as investors look beyond COVID in Q4https://pharmaphorum.com/r-d/views-analysis-r-d/pharmas-pipeline-continues-to-provide-drama-as-investors-look-beyond-covid-in-q4/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
Eisai forges CNS alliance with UK’s Wren TherapeuticsJapanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for Share XEisai forges CNS alliance with UK’s Wren Therapeuticshttps://pharmaphorum.com/news/eisai-forges-cns-alliance-with-uks-wren-therapeutics/
Biogen bulks up pipeline with Sage drugs in $3bn dealWith the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore Share XBiogen bulks up pipeline with Sage drugs in $3bn dealhttps://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarNovartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its Share XFDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarhttps://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
Bridging the gap between pharma and the NHS in MSJanette Curlis is a Multiple Sclerosis Nurse Advisor (MSNA) at Biogen, helping to support the company’s Multiple Sclerosis Share XBridging the gap between pharma and the NHS in MShttps://pharmaphorum.com/views-analysis-patients/bridging-gap-between-pharma-nhs-in-ms/
FDA panel unimpressed with data for Alzheimer’s drug aducanumabThe FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors Share XFDA panel unimpressed with data for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/fda-sceptical-on-biogen-eisai-data-for-alzheimers-drug-aducanumab/
